- 期刊
- OpenAccess
肥胖治療藥物之最新進展：Phentermine/Topiramate複方
Advances in the Treatment of Obesity: The Combination of Phentermine and Topiramate
並列摘要
Obesity is a major risk factor for numerous chronic diseases and a global health-related issue. Many drugs used for weight loss have been withdrawn from the market for safety reasons, and only a few medications are currently approved for the long-term treatment of obesity. In July 2012, U.S. Food and Drug Administration approved the combination of phentermine and topiramate as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (body mass index, BMI of ≥30kg/m^2) or overweight adults (BMI≥27kg/m^2) having at least one obesity-related comorbidity (e.g., type 2 diabetes mellitus, hypertension, or hyperlipidemia). This article provides health professionals with concise information about the pharmacological action underlying their combined use and the results of clinical trials.
參考文獻
延伸閱讀
- 廖美齡、施承典（2003）。減肥藥之新發展。台灣醫學，7(2)，263-271。https://doi.org/10.6320/FJM.2003.7(2).17
- 當代醫學編輯部（2010）。文獻選粹：減肥藥的研究新進展─naltrexone加上bupropion。當代醫學，(446)，926-926。https://doi.org/10.29941/MT.201012.0007
- 周美佳（2016）。探討種子胜肽Lunasin對於肥胖引起的發炎模式之免疫調節作用〔碩士論文，國立臺灣師範大學〕。華藝線上圖書館。https://doi.org/10.6345/NTNU202204040
- 蘇鉯喬（2017）。Repaglinide併Metformin複方與Repaglinide單方在第二型糖尿病病人血糖控制的療效差異研究〔碩士論文，長榮大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0015-0210201714110800
- Pergola, G. D., Nardecchia, A., Ammirati, A., Caccavo, D., Bavaro, S., & Silvestris, F. (2012). Abdominal Obesity Is Characterized by Higher Pulse Pressure: Possible Role of Free Triiodothyronine. Journal of Obesity, 2012(), 744-748. https://doi.org/10.1155/2012/656303